drugset / Trial / NCT01113801
A Study in Participants With Diabetic Kidney Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
Timeline
- Start
- 2010-07
- Primary completion
- 2014-05
- Completion
- 2014-07
Outcome
Outcome not reported
Stopped: “Interim Assessment: Lack of Efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2382770 | Unknown | 2 mg | Subcutaneous |
| Subject | LY2382770 | Unknown | 10 mg | Subcutaneous |
| Subject | LY2382770 | Unknown | 50 mg | Subcutaneous |